Program
suvemcitug
Also written as “Sevacizumab”, “BD0801” and “Suvemcitug injection, trifluridine/tipiracil tablets”.
Its studies are mostly in Colorectal Neoplasms · Ovarian Neoplasms, led by Simcere Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 61 open or running | phase 3since May 27, 2021 | Apr 26, 2013 | Jan 2028phase 3 · NCT07361003 |
Also a collaborator on its studies: shanghai-xianxiang-medical-technology-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2013First study: phase 1 study in Advanced Solid TumorsFirst studyNCT01847118 · 31 enrolled · China
- May 19, 2015Phase 1 study in Colorectal NeoplasmsNCT02453464 · 36 enrolled · China
- Nov 25, 2018Phase 1 study in Ovarian NeoplasmsNCT03763123 · 48 enrolled · China
- May 27, 2021Phase 3 study in Ovarian NeoplasmsNCT04908787 · 421 enrolled · China
- Nov 15, 2021Phase 2 study in Advanced Solid TumorNCT05148195 · 86 enrolled · China
- Sep 30, 2025Phase 3 study in Colorectal NeoplasmsNCT07361003 · 464 planned · China
Ahead
- Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07361003
TargetBeta
“A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| Ranibizumabrule | Novartis | phase 4 | 108 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07361003Colorectal Neoplasms · China | 3 | Recruiting | Jan 2028 | 464 |
| NCT05148195Advanced Solid Tumor · China | 2 | Terminated | Jul 26, 2023 | 86 |
| NCT04908787Ovarian Neoplasms · China | 3 | Completed | Dec 8, 2023 | 421 |
| NCT03763123Ovarian Neoplasms · China | 1 | UNKNOWN | Dec 31, 2019 | 48 |
| NCT02453464Colorectal Neoplasms · China | 1 | UNKNOWN | Dec 2016 | 36 |
| NCT01847118Advanced Solid Tumors · China | 1 | UNKNOWN | Nov 2015 | 31 |
How it is read
Names in the registry
- “Sevacizumab”, 3 entries
- “BD0801”, 2 entries
- “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.